Related references
Note: Only part of the references are listed.Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer
Shan-Shan Hong et al.
DRUG DELIVERY (2018)
Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target
Alfredo Perales-Puchalt et al.
CLINICAL CANCER RESEARCH (2017)
Enhanced Oncolytic Activities of the Telomerase-Specific Replication-Competent Adenovirus Expressing Short-Hairpin RNA against Dicer
Mitsuhiro Machitani et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Major clinical research advances in gynecologic cancer in 2016: 10-year special edition
Dong Hoon Suh et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2017)
Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma
Chen Liang et al.
MOLECULAR CANCER RESEARCH (2017)
Advances in the delivery of RNA therapeutics: from concept to clinical reality
James C. Kaczmarek et al.
GENOME MEDICINE (2017)
Synthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy
Lior Nissim et al.
CELL (2017)
Triptorelin Tethered Multifunctional PAMAM-Histidine-PEG Nanoconstructs Enable Specific Targeting and Efficient Gene Silencing in LHRH Overexpressing Cancer Cells
Prajakta Tambe et al.
ACS APPLIED MATERIALS & INTERFACES (2017)
Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth
Thapi Dharma Rao et al.
ACS CHEMICAL BIOLOGY (2017)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB
Micaela Morgado et al.
ONCOTARGET (2016)
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments
J. A. Ledermann et al.
ANNALS OF ONCOLOGY (2015)
Gene therapy for cancer: regulatory considerations for approval
S. R. Husain et al.
CANCER GENE THERAPY (2015)
Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy
Srustidhar Das et al.
CANCER RESEARCH (2015)
Tissue Specific Promoters in Colorectal Cancer
A. R. Rama et al.
DISEASE MARKERS (2015)
Mucin Expression in Endoscopic Ultrasound-Guided Fine-Needle Aspiration Specimens Is a Useful Prognostic Factor in Pancreatic Ductal Adenocarcinoma
Michiyo Higashi et al.
PANCREAS (2015)
MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer
Renee M. Tholey et al.
MOLECULAR CANCER RESEARCH (2015)
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
Mildred Felder et al.
MOLECULAR CANCER (2014)
Quantitative Analysis of Serum IgG Galactosylation Assists Differential Diagnosis of Ovarian Cancer
Yifan Qian et al.
JOURNAL OF PROTEOME RESEARCH (2013)
Targeted gene silencing using a follicle-stimulating hormone peptide-conjugated nanoparticle system improves its specificity and efficacy in ovarian clear cell carcinoma in vitro
Shanshan Hong et al.
JOURNAL OF OVARIAN RESEARCH (2013)
Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT
J. C. Doloff et al.
CANCER GENE THERAPY (2011)
Enhanced Safety Profiles of the Telomerase-Specific Replication-Competent Adenovirus by Incorporation of Normal Cell-Specific microRNA-Targeted Sequences
Kumiko Sugio et al.
CLINICAL CANCER RESEARCH (2011)
More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis
Robert C. Bast et al.
GYNECOLOGIC ONCOLOGY (2011)
Epigenetic regulation of mucin genes in human cancers
Norishige Yamada et al.
CLINICAL EPIGENETICS (2011)
Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax
H. Garg et al.
CANCER GENE THERAPY (2010)
A Hypoxia- and α-Fetoprotein-Dependent Oncolytic Adenovirus Exhibits Specific Killing of Hepatocellular Carcinomas
Oh-Joon Kwon et al.
CLINICAL CANCER RESEARCH (2010)
Conflicting views on the molecular structure of the cancer antigen CA125/MUC16
Houda Bouanene et al.
DISEASE MARKERS (2010)
Follicle-Stimulating Hormone Peptide Can Facilitate Paclitaxel Nanoparticles to Target Ovarian Carcinoma In vivo
Xiao-yan Zhang et al.
CANCER RESEARCH (2009)
Tissue Specific Cytotoxicity of Colon Cancer Cells Mediated by Nanoparticle-delivered Suicide Gene In vitro and In vivo
Guiying Zhang et al.
CLINICAL CANCER RESEARCH (2009)
Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer
Miguel A. Trujillo et al.
BREAST CANCER RESEARCH (2009)
Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUG-1 promoter
Peng Gao et al.
CANCER LETTERS (2007)
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis
Gong Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter
RM Dwyer et al.
CLINICAL CANCER RESEARCH (2005)
The CA 125 gene: An extracellular superstructure dominated by repeat sequences
TJ O'Brien et al.
TUMOR BIOLOGY (2001)
Molecular cloning of the CA125 ovarian cancer antigen - Identification as a new mucin, MUC16
BWT Yin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
